China is reportedly considering approving the Russian cancer vaccine Enteromix, designed to train the immune system to directly target and destroy cancer cells. This development could challenge the dominance of multi-billion-dollar global pharmaceutical companies and redefine cancer treatment.
Enteromix has completed preclinical trials in animals, showing 60–80% tumor reductions. Early Phase I human trials focused on immune system activation. Initially developed for colorectal cancer, the vaccine is now being explored for glioblastoma and ocular melanoma, though larger studies are required to confirm safety and efficacy.
If proven effective, Enteromix could reduce reliance on long-term, expensive drug therapies, potentially providing a cost-effective alternative for millions of patients. While still limited to Russia and pending regulatory approvals, China’s interest signals a potential collaboration that could bring groundbreaking cancer therapies to a wider population.
Related stories:
China identifies natural compound to block liver cancer growth
